Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Actinium Phamaceuticals, Inc.”

20 pharma patents match "Actinium Phamaceuticals, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 20
Index total 30,257
Page 1 / 1

Quick answer

This filtered view shows 20 pharmaceutical patents matching "Actinium Phamaceuticals, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

20 results for “Actinium Phamaceuticals, Inc.” · 30,257 patents in full index Clear search

  1. US 12410249

    Low dose antibody-based methods for treating hematologic malignancies

    Actinium Phamaceuticals, Inc. · Granted Sep 9, 2025 · Expires Sep 4, 2045

    granted
  2. US 12133849

    Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha- emitting radioimmunotherapeutic

    Actinium Phamaceuticals, Inc. · Granted Nov 5, 2024 · Expires Oct 31, 2044

    granted
  3. US 12083192

    Methods for treatment of patients with myelodysplastic syndromes

    Actinium Phamaceuticals, Inc. · Granted Sep 10, 2024 · Expires Sep 5, 2044

    granted
  4. US 11981741

    Humanized anti-CD45 antibodies

    Actinium Phamaceuticals, Inc. · Granted May 14, 2024 · Expires May 9, 2044

    granted
  5. US 11975081

    Bifunctional chelators and conjugates

    Actinium Phamaceuticals, Inc. · Granted May 7, 2024 · Expires May 2, 2044

    granted
  6. US 11964948

    Bifunctional chelators and conjugates

    Actinium Phamaceuticals, Inc. · Granted Apr 23, 2024 · Expires Apr 18, 2044

    granted
  7. US 11912780

    Anti-CD45-based conditioning methods and uses thereof in conjunction with gene-edited cell-based therapies

    Actinium Phamaceuticals, Inc. · Granted Feb 27, 2024 · Expires Feb 22, 2044

    granted
  8. US 11844799

    Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeutic

    Actinium Phamaceuticals, Inc. · Granted Dec 19, 2023 · Expires Dec 14, 2043

    granted
  9. US 11406724

    Stabilized radiolabeled anti-CD45 immunoglobulin compositions

    Actinium Phamaceuticals, Inc. · Granted Aug 9, 2022 · Expires Aug 4, 2042

    granted
  10. US 11364235

    Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeutic

    Actinium Phamaceuticals, Inc. · Granted Jun 21, 2022 · Expires Jun 16, 2042

    granted
  11. US 11292835

    Low dose antibody-based methods for treating hematologic malignancies

    Actinium Phamaceuticals, Inc. · Granted Apr 5, 2022 · Expires Mar 31, 2042

    granted
  12. US 11241512

    Stabilized radio-labeled anti-CD45 immunoglobulin compositions

    Actinium Phamaceuticals, Inc. · Granted Feb 8, 2022 · Expires Feb 3, 2042

    granted
  13. US 10736975

    Infusion administration of conjugated monoclonal antibodies

    Actinium Phamaceuticals, Inc. · Granted Aug 11, 2020 · Expires Aug 6, 2040

    granted
  14. US 10420851

    Stabilized radiolabeled anti-CD45 immunoglobulin compositions

    Actinium Phamaceuticals, Inc. · Granted Sep 24, 2019 · Expires Sep 19, 2039

    granted
  15. US 9790573

    Method for purification of 225AC from irradiated 226RA-targets

    Actinium Phamaceuticals, Inc. · Granted Oct 17, 2017 · Expires Oct 12, 2037

    granted
  16. US 9603954

    Methods for generating radioimmunoconjugates

    Actinium Phamaceuticals, Inc. · Granted Mar 28, 2017 · Expires Mar 23, 2037

    granted
  17. US 9534277

    Method for purification of 225AC from irradiated 226RA-targets

    Actinium Phamaceuticals, Inc. · Granted Jan 3, 2017 · Expires Dec 29, 2036

    granted
  18. US 8349391

    Radium target and method for producing it

    Actinium Phamaceuticals, Inc. · Granted Jan 8, 2013 · Expires Jan 3, 2033

    granted
  19. US 7374936

    Method and means for site directed therapy

    Actinium Phamaceuticals, Inc. · Granted May 20, 2008 · Expires May 15, 2028

    granted
  20. US 6403771

    Method and means for site directed therapy

    Actinium Phamaceuticals, Inc. · Granted Jun 11, 2002 · Expires Jun 6, 2022

    expired